东方生物(688298) - 2022 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2022 was ¥746,518,004.45, a decrease of 26.72% compared to the same period last year[5]. - The net profit attributable to shareholders for Q3 2022 was ¥309,888,878.97, down 40.98% year-over-year[5]. - The net profit after deducting non-recurring gains and losses for Q3 2022 was ¥321,113,715.78, a decrease of 38.91% compared to the previous year[5]. - The basic earnings per share for Q3 2022 was ¥1.84, reflecting a decline of 57.99% year-over-year[5]. - The total net profit attributable to shareholders of the parent company was CNY 3,051,534,400.78, a decrease of approximately 22.1% compared to CNY 3,919,267,583.04 in the previous period[35]. - The operating profit for the period was CNY 3,695,276,938.50, down from CNY 4,616,040,989.33, reflecting a decline of about 19.9%[35]. - The total comprehensive income attributable to the parent company's owners was CNY 3,120,703,964.77, compared to CNY 3,920,412,028.70 in the previous period, indicating a decrease of approximately 20.5%[38]. - The total profit for the period was CNY 3,653,295,769.51, compared to CNY 4,610,206,289.31 in the previous period, representing a decline of about 20.8%[35]. Cash Flow and Liquidity - The net cash flow from operating activities for the year-to-date decreased by 54.77% to ¥1,898,330,416.44[5]. - The net cash flow from operating activities was CNY 1,898,330,416.44, significantly lower than CNY 4,197,448,196.49 in the previous period, representing a decline of about 54.7%[41]. - Cash inflows from operating activities totaled CNY 9,452,389,461.32, an increase from CNY 7,680,019,835.27, marking a growth of approximately 23.1%[39]. - The company reported a net cash outflow from investing activities of CNY 695,367,323.21, slightly higher than the previous period's outflow of CNY 690,076,969.20[41]. - The cash and cash equivalents at the end of the period amounted to CNY 7,082,482,916.75, up from CNY 4,787,584,604.49, reflecting an increase of approximately 48.0%[41]. Research and Development - The total R&D investment for the year-to-date was ¥400,235,056.53, an increase of 64.69% compared to the same period last year[7]. - Research and development expenses amounted to ¥400,235,056.53 in the first three quarters of 2022, up from ¥243,025,375.01 in 2021, reflecting a growth of approximately 64.67%[32]. Assets and Liabilities - The total assets at the end of the reporting period were ¥11,069,169,598.37, representing a 23.31% increase from the end of the previous year[7]. - The total assets as of the end of the reporting period were ¥11,069,169,598.37, compared to ¥8,976,971,218.27 at the end of the previous year, marking an increase of about 23.66%[30]. - The total liabilities decreased to ¥1,688,267,765.90 from ¥2,088,182,033.02, a reduction of approximately 19.19%[30]. - The equity attributable to shareholders reached ¥9,240,007,311.55, up from ¥6,857,173,515.60, indicating an increase of about 34.56%[30]. Shareholder Information - Total number of common shareholders at the end of the reporting period is 21,470, with the top 10 shareholders holding a combined 66.5% of shares[17]. - The largest shareholder, Anji Fulanglai Import and Export Trade Co., Ltd., holds 32,760,000 shares, representing 19.5% of total shares[17]. - The report indicates no significant changes in the status of pledged or frozen shares among major shareholders[17]. Market and Strategic Outlook - The company experienced a significant decline in sales revenue due to further price reductions of products, impacting overall profitability[11]. - The company has not disclosed any significant new product developments or technological advancements during the reporting period[19]. - There are no indications of market expansion or mergers and acquisitions in the current report[19]. - The company has not provided specific future outlook or performance guidance in the conference call[19]. - The company plans to expand its market presence and invest in new product development, although specific figures were not disclosed[30]. - The company has indicated a focus on strategic acquisitions to enhance its competitive position in the market[30]. Inventory and Receivables - Inventory has significantly increased to ¥1,205,351,251.66 from ¥470,562,194.65 year-over-year[23]. - Accounts receivable decreased to ¥567,379,087.11 from ¥1,184,430,196.42, indicating improved collection efficiency[23].